Edgar Filing: Genpact LTD - Form 4

Genpact LT Form 4	D									
March 07, 2 FORN Check th	14 UNITEI is box) STATES		RITIES A shington,			NGE C	OMMISSION	OMB AF OMB Number: Expires:	PROVAL 3235-0287 January 31,
subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Estimated a burden hour response				
(Print or Type 1 1. Name and A Thukral Mc	Address of Reportin	g Person <u>*</u>	Symbol	r Name and t LTD [G		Tradin	Ig	5. Relationship of Issuer		
	^(First) ACT LLC, 105 AVENUE, 2NI	(Middle)	3. Date of (Month/E 03/05/2	-	ransaction			Director X Officer (give below)		Owner r (specify
NEW YOR	(Street) K, NY 10016			endment, Da nth/Day/Year	-			6. Individual or Jo Applicable Line) _X_ Form filed by C Form filed by M Person	one Reporting Per	rson
(City)	(State)	(Zip)	Tabl	le I - Non-I	Derivative S	Securi	ities Acqu	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year) Executio any	n Date, if	3. Transactio Code (Instr. 8)	4. Securit or(A) or Dis (Instr. 3, 4	sposed	l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	03/05/2014			Code V A	Amount 57,919 (1)	(D) A	Price \$ 0	(Instr. 3 and 4) 110,849	D	
Common Shares	03/05/2014			F	19,687 (2)	D	\$ 16.71	91,162	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Genpact LTD - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	 3A. Deemed Execution Date, if any (Month/Day/Year) 	4. Transactio Code (Instr. 8)	5. 6. Date Exercisable and ionNumber Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date	7. Title Amoun Underl Securit (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
Beno	rtina O)wners		Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

τερυιτικ

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Thukral Mohit C/O GENPACT LLC 105 MADISON AVENUE, 2ND FLOOR NEW YORK, NY 10016			Senior Vice Presider	nt		
Signatures						
/s/ Heather White, as Attorney-in-fact for Mohit Thukral		03	8/07/2014			
**Signature of Reporting Person			Date			

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents shares issued upon the vesting of performance share units (PSUs) granted on March 15, 2011 under the Genpact Limited 2007 (1) Omnibus Incentive Compensation Plan. Vesting was based on achieving certain average organic revenue growth and average organic adjusted income from operations growth targets during the January 1, 2011 - December 31, 2013 performance period.
- (2) Represents shares withheld for payment of taxes upon the vesting of the PSUs described in footnote 1.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Total liabilities 24,559,000 (749,000) 23,810,000 Shareholders equity 48,714,000 1,664,000 3 50,378,000 Total liabilities and shareholdersequity\$73,273,000\$915,000\$74,188,000

Notes to Pro forma balance sheet as of June 30, 2004:

- 1 To reflect net liabilities assumed in acquisition and the application of deposits used to fund pre-closing operating costs.
- 2 To reflect the estimated fair value of investment in common shares of Chromos and debenture received as purchase price consideration.
- 3 To reflect the effect on equity of the estimated gain from the disposition of CellExSys consisting of the estimated fair value of the purchase price consideration and the value of net liabilities assumed and deposits applied to fund pre-closing operating costs. The actual purchase price consideration is subject to adjustment in accordance with the terms of the merger agreement. As a result, the actual gain we report may differ from the estimated gain presented in this pro forma balance sheet.

3

Table of Contents

The following tables reflect unaudited pro forma results of operations assuming the disposition of CellExSys, giving effect to the disposition as if it had occurred at the beginning of each respective period. The pro forma results, do not give effect to any gain resulting from the disposition of CellExSys, which will be reflected in the period ending September 30, 2004, and will consist of the net liabilities assumed by Chromos, the deposits received from Chromos to fund pre-closing operating costs, and our pro-rata share of the fair value of the merger consideration. The pro forma results of operations are not necessarily indicative of the actual results of operations that would have occurred had the disposition of CellExSys actually occurred as of the beginning of each period presented.

	December 31, 2003	Pro forma Adjustments	Notes	December 31, 2003
	(historical)			(pro forma)
Revenue under collaborative				
agreements	\$ 14,073,000	\$		\$ 14,073,000
Operating expenses:				
Research & development	17,197,000	(1,518,000)	1	15,679,000
General & administrative	5,490,000	(483,000)	1	5,007,000
Restructure charges	5,190,000			5,190,000
Total operating expenses	27,877,000	(2,001,000)		25,876,000
Loss from operations	(13,804,000)	2,001,000		(11,803,000)
Other expense, net	(1,029,000)	54,000	2	(975,000)
Net loss	\$(14,833,000)	\$ 2,055,000		\$(12,778,000)
Net loss per common share Shares used in computation	\$ (0.26) 57,486,000			\$ (0.22) 57,486,000
	June 30, 2004	Pro forma Adjustments	Notes	June 30, 2004

	June 30, 2004	Adjustments	Notes	June 30, 2004
	(historical)			(pro forma)
Revenue under collaborative agreements Operating expenses:	\$ 4,081,000	\$		\$ 4,081,000
Research & development	9,065,000	(620,000)	1	8,445,000
General & administrative	3,816,000	(236,000)	1	3,580,000
Restructure charges	416,000			416,000
Total operating expenses	13,297,000	(856,000)		12,441,000

Edgar Filing: Genpact LTD - Form 4

Loss from operations Other expense, net	(9,216,000) (92,000)	856,000 27,000	2	(8,360,000) (65,000)
Net loss	\$ (9,308,000)	\$ 883,000		\$ (8,425,000)
Net loss per common share Shares used in computation	\$ (0.12) 77,239,000			\$ (0.11) 77,239,000

Notes to pro forma statements of operations:

- 1 To eliminate the operating costs which cease as a result of the disposition of CellExSys. These amounts do not include corporate overhead costs that had previously been allocated to CellExSys for accounting purposes.
- 2 To reflect interest income on debenture from beginning of period at an assumed rate of 10%.

Table of Contents

- (c) *Exhibits*.
 - Exhibit 2.1 Agreement and Plan of Merger, dated June 21, 2004, by and among, Chromos, Chromos, Inc., CellExSys and Targeted Genetics (incorporated by reference to Exhibit 10.2 to Targeted Genetics quarterly report on Form 10-Q for the quarter ended June 30, 2004, filed with the Commission on July 30, 2004).

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

Date: August 11, 2004

By: /s/ Todd E. Simpson

Todd E. Simpson Vice President, Finance and Administration and Chief Financial Officer, Secretary and Treasurer (Principal Financial and Accounting Officer)

6

EXHIBIT INDEX

Table of Contents

Exhibit No. Description 2.1 Agreement and Plan of Merger, dated June 21, 2004, by and among, Chromos, Chromos, Inc., CellExSys and Targeted Genetics (incorporated by reference to Exhibit 10.2 to Targeted Genetics quarterly report on Form 10-Q for the quarter ended June 30, 2004, filed with the Securities and Exchange Commission on July 30, 2004).

7